Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 577 participants.

Also called NCT03191396

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 577 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03191396
  • EudraCT 2016-004965-22
Other papers using this trial's data
  • Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) Diabetes & metabolism, 2020-04 DOI, PubMed 31539622

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Bulgaria, Czechia, Finland, France, Germany, Hungary, Italy, Poland, Slovenia, Spain, Sweden, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03191396. Randomized; no masking; primary purpose treatment. Start 2017-06-27 (actual); primary completion 2018-07-09 (actual). Results posted on 2019-08-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
Acronym
SUSTAIN 10
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Liraglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03191396
Content hash
51aaac0215a16f76f961fcf69660a261941c1112e57924e59d4c4d9f1e63683e